Evidence map›Paper›PMID 30159621›Full record

ArticleEuropean radiology2019

Hepatocellular carcinoma: CT texture analysis as a predictor of survival after surgical resection.

Lucie Brenet Defour, Sébastien Mulé, Arthur Tenenhaus, Tullio Piardi, Daniele Sommacale, Christine Hoeffel, Gérard Thiéfin

Abstract read
PubMed Publisher
In one paragraph

Article in European radiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Texture analysis of [European journal of nuclear medicine and molecular imaging · 2026
    Observational
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Focal Lesions of the Liver and Radiomics: What Do We Know?Diagnostics (Basel, Switzerland) · 2023
    Review
  15. Article
  16. Article
  17. Radiomics in Breast Imaging: Future Development.Journal of personalized medicine · 2023
    Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lucie Brenet DefourService d'Hépato-Gastroentérologie et de Cancérologie Digestive, Centre Hospitalier Universitaire de Reims, 51092, Reims, France.
Sébastien MuléService d'Imagerie Médicale, Centre Hospitalier Universitaire de Reims, Reims, France.
Arthur TenenhausLaboratoire des Signaux et Systèmes, CentraleSupélec, Université Paris-Saclay, Gif sur Yvette, France.
Tullio PiardiService de Chirurgie Générale, Digestive et Endocrine, Centre Hospitalier Universitaire de Reims, Reims, France.
Daniele SommacaleService de Chirurgie Générale, Digestive et Endocrine, Centre Hospitalier Universitaire de Reims, Reims, France.
Christine HoeffelService d'Imagerie Médicale, Centre Hospitalier Universitaire de Reims, Reims, France.
Gérard ThiéfinService d'Hépato-Gastroentérologie et de Cancérologie Digestive, Centre Hospitalier Universitaire de Reims, 51092, Reims, France. gthiefin@chu-reims.fr.ORCID http://orcid.org/0000-0002-8626-8352

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo determine whether image texture parameters analysed on pre-operative contrast-enhanced computed tomography (CT) can predict overall survival and recurrence-free survival in patients with hepatocellular carcinoma (HCC) treated by surgical resection.

methodsWe retrospectively included all patients operated for HCC who had liver contrast-enhanced CT within 3 months prior to treatment in our centre between 2010 and 2015. The following texture parameters were evaluated on late-arterial and portal-venous phases: mean grey-level, standard deviation, kurtosis, skewness and entropy. Measurements were made before and after spatial filtration at different anatomical scales (SSF) ranging from 2 (fine texture) to 6 (coarse texture). Lasso penalised Cox regression analyses were performed to identify independent predictors of overall survival and recurrence-free survival.

resultsForty-seven patients were included. Median follow-up time was 345 days (interquartile range [IQR], 176-569). Nineteen patients had a recurrence at a median time of 190 days (IQR, 141-274) and 13 died at a median time of 274 days (IQR, 96-411). At arterial CT phase, kurtosis at SSF = 4 (hazard ratio [95% confidence interval] = 3.23 [1.35-7.71] p = 0.0084) was independent predictor of overall survival. At portal-venous phase, skewness without filtration (HR [CI 95%] = 353.44 [1.31-95102.23], p = 0.039), at SSF2 scale (HR [CI 95%] = 438.73 [2.44-78968.25], p = 0.022) and SSF3 (HR [CI 95%] = 14.43 [1.38-150.51], p = 0.026) were independently associated with overall survival. No textural feature was identified as predictor of recurrence-free survival.

conclusionsIn patients with resectable HCC, portal venous phase-derived CT skewness is significantly associated with overall survival and may potentially become a useful tool to select the best candidates for resection. KEY POINTS: • HCC heterogeneity as evaluated by texture analysis of contrast-enhanced CT images may predict overall survival in patients treated by surgical resection. • Among texture parameters, skewness assessed at different anatomical scales at portal-venous phase CT is an independent predictor of overall survival after resection. • In patients with HCC, CT texture analysis may have the potential to become a useful tool to select the best candidates for resection.

Indexed as

HepatectomyAdultAgedAged, 80 and overCarcinoma, HepatocellularFemaleFranceHumansLiver NeoplasmsMaleMiddle AgedMultidetector Computed TomographyPostoperative PeriodPrognosisRetrospective StudiesSurvival RateComputed tomographyComputer-assisted image analysisLiverNeoplasmSurvival

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.